Literature DB >> 25682604

Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis.

Elisabeth P C Plompen1, Peter J M Valk2, Isabel Chu2, Sarwa Darwish Darwish Murad1, Aurelie Plessier3, Fanny Turon4, Jonel Trebicka5, Massimo Primignani6, Juan Carlos Garcia-Pagán4, Dominique C Valla3, Harry L A Janssen7, Frank W G Leebeek8.   

Abstract

Entities:  

Keywords:  Budd-Chiari syndrome; calreticulin; mutations; portal vein thrombosis; somatic

Mesh：

Substances：

Year:  2015        PMID： 25682604      PMCID： PMC4450635          DOI： 10.3324/haematol.2014.120857

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  17 in total

1.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

2.  Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome.

Authors:  Jildou Hoekstra; Ana H C Guimarães; Frank W G Leebeek; Sarwa Darwish Murad; Joyce J M C Malfliet; Aurelie Plessier; Manuel Hernandez-Guerra; Philippe Langlet; Elwyn Elias; Jonel Trebicka; Massimo Primignani; Juan-Carlos Garcia-Pagan; Dominique C Valla; Dingeman C Rijken; Harry L A Janssen
Journal:  Blood       Date:  2009-11-18       Impact factor: 22.113

Review 3.  Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.

Authors:  Jasper H Smalberg; Lidia R Arends; Dominique C Valla; Jean-Jacques Kiladjian; Harry L A Janssen; Frank W G Leebeek
Journal:  Blood       Date:  2012-10-04       Impact factor: 22.113

4.  Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding.

Authors:  M C W Spaander; J Hoekstra; B E Hansen; H R Van Buuren; F W G Leebeek; H L A Janssen
Journal:  J Thromb Haemost       Date:  2013-03       Impact factor: 5.824

5.  Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis.

Authors:  Fanny Turon; Francisco Cervantes; Dolors Colomer; Anna Baiges; Virginia Hernández-Gea; Juan Carlos Garcia-Pagán
Journal:  J Hepatol       Date:  2014-08-27       Impact factor: 25.083

6.  Etiology, management, and outcome of the Budd-Chiari syndrome.

Authors:  Sarwa Darwish Murad; Aurelie Plessier; Manuel Hernandez-Guerra; Federica Fabris; Chundamannil E Eapen; Matthias J Bahr; Jonel Trebicka; Isabelle Morard; Luc Lasser; Joerg Heller; Antoine Hadengue; Philippe Langlet; Helena Miranda; Massimo Primignani; Elwyn Elias; Frank W Leebeek; Frits R Rosendaal; Juan-Carlos Garcia-Pagan; Dominique C Valla; Harry L A Janssen
Journal:  Ann Intern Med       Date:  2009-08-04       Impact factor: 25.391

7.  Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study.

Authors:  Aurelie Plessier; Sarwa Darwish-Murad; Manuel Hernandez-Guerra; Yann Consigny; Federica Fabris; Jonel Trebicka; Jorg Heller; Isabelle Morard; Luc Lasser; Philippe Langlet; Marie-Hélène Denninger; Dominique Vidaud; Bertrand Condat; Antoine Hadengue; Massimo Primignani; Juan-Carlos Garcia-Pagan; Harry L A Janssen; Dominique Valla
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

8.  Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.

Authors:  Giada Rotunno; Carmela Mannarelli; Paola Guglielmelli; Annalisa Pacilli; Alessandro Pancrazzi; Lisa Pieri; Tiziana Fanelli; Alberto Bosi; Alessandro M Vannucchi
Journal:  Blood       Date:  2013-12-26       Impact factor: 22.113

9.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

10.  JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Authors:  Elisa Rumi; Daniela Pietra; Virginia Ferretti; Thorsten Klampfl; Ashot S Harutyunyan; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Chiara Elena; Ilaria C Casetti; Chiara Milanesi; Emanuela Sant'antonio; Marta Bellini; Elena Fugazza; Maria C Renna; Emanuela Boveri; Cesare Astori; Cristiana Pascutto; Robert Kralovics; Mario Cazzola
Journal:  Blood       Date:  2013-12-23       Impact factor: 22.113
View more
  6 in total

Review 1.  Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs).

Authors:  Wenyi Luo; Zhongxin Yu
Journal:  Stem Cell Investig       Date:  2015-08-31

Review 2.  Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.

Authors:  Joan How; Amy Zhou; Stephen T Oh
Journal:  Ther Adv Hematol       Date:  2016-12-08

3.  Esophageal location of mantle cell lymphoma.

Authors:  Spyros Michopoulos
Journal:  Ann Gastroenterol       Date:  2016-09-06

4.  CALR mutation analysis is not indicated in patients with splanchnic vein thrombosis without evidence of a myeloproliferative neoplasm: a micro-review.

Authors:  Stephen E Langabeer
Journal:  Ann Gastroenterol       Date:  2016-06-10

5.  Detecting CALR Mutations in Splanchnic Vein Thrombosis: Who and How?

Authors:  Stephen E Langabeer
Journal:  J Transl Int Med       Date:  2018-06-26

6.  γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm.

Authors:  Jan Görtzen; Lena M Hunka; Maria Vonnahme; Michael Praktiknjo; Andrea Kaifie; Rolf Fimmers; Christian Jansen; Annkristin Heine; Jennifer Lehmann; Joachim R Goethert; Norbert Gattermann; Eray Goekkurt; Uwe Platzbecker; Peter Brossart; Christian P Strassburg; Tim H Brummendorf; Steffen Koschmieder; Dominik Wolf; Jonel Trebicka
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.